Plaintiffs allege that Bristol-Myers Squibb and Otsuka Pharmaceutical failed to warn doctors and patients about the risk for compulsive behaviors when taking the atypical antipsychotic Abilify.
Support MIA
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.